NewEdge Wealth LLC raised its holdings in CVS Health Corporation (NYSE:CVS – Free Report) by 48.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 25,099 shares of the pharmacy operator’s stock after buying an additional 8,200 shares during the period. NewEdge Wealth LLC’s holdings in CVS Health were worth $1,992,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sei Investments Co. raised its holdings in CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after purchasing an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after purchasing an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina increased its position in shares of CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after purchasing an additional 7,588 shares in the last quarter. HUB Investment Partners LLC increased its position in shares of CVS Health by 25.0% during the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after purchasing an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of CVS Health by 8.0% during the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock worth $111,017,000 after purchasing an additional 119,439 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.
CVS Health Stock Performance
Shares of CVS stock opened at $95.19 on Wednesday. The stock has a market capitalization of $121.45 billion, a PE ratio of 41.93, a price-to-earnings-growth ratio of 0.90 and a beta of 0.60. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $95.36. The stock’s 50-day moving average price is $77.74 and its 200 day moving average price is $78.24. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.
CVS Health Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s payout ratio is currently 117.18%.
CVS Health News Summary
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: JPMorgan and Sanford C. Bernstein both raised their price targets on CVS and kept bullish ratings, signaling confidence that the stock still has room to run after its strong Q1 results. JPMorgan and Bernstein price target updates
- Positive Sentiment: TD Cowen also lifted its target and reiterated a buy rating, adding to the recent analyst optimism around CVS Health’s earnings momentum and raised full-year guidance. TD Cowen adjusts price target on CVS Health to 110 from 105
- Positive Sentiment: Recent commentary says CVS is still cheap relative to its improving earnings, revenue growth, and margins, with Q1 showing better profitability and management raising 2026 guidance. CVS Health: Still Cheap And Signs Of Improvement
- Positive Sentiment: CVS is also benefiting from business updates that favor lower-cost biosimilars in its commercial formularies, which could support cost control and improve competitiveness in pharmacy benefits. CVS Health Corporation Updates its Commercial Formularies
- Neutral Sentiment: The company disclosed insider selling by EVP Tilak Mandadi, who sold 69,551 shares. The size is notable, but it does not necessarily indicate a change in the company’s outlook. SEC Form 4 filing
- Neutral Sentiment: Additional articles and market chatter continue to highlight CVS as a value and dividend name, reinforcing the bullish tone but not adding a major new catalyst. CVS Health is a Top-Ranked Growth Stock
Insider Transactions at CVS Health
In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on CVS shares. DA Davidson lifted their target price on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Bank of America cut their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. Wells Fargo & Company lifted their target price on shares of CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a report on Friday. Piper Sandler cut their target price on shares of CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a report on Tuesday, March 31st. Finally, Wolfe Research cut their target price on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.00.
Check Out Our Latest Stock Report on CVS Health
CVS Health Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
- Five stocks we like better than CVS Health
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
